Abstract
Introduction: Studies suggest that pneumococcal and flu vaccines can prevent pneumonia and exacerbations in COPD patients. In our study, we aimed to determine how the 13-valent conjugated pneumococcal vaccine (KPA13) administered to COPD patients affected the exacerbation frequency at the end of one year compared to the previous year.
Results: The data of 138 cases included in the study were analyzed. There was no difference in mean FEV1 values, median number of exacerbations in the last year, median CAT and mMRC scores between two groups (70 patients who were vaccinated and 68 patients who were not vaccinated) (p> 0.05). In the group vaccinated with KPA13, the median number of exacerbations (min-max) last year was 1.0 (0.0-5.0), it was 0 (0.0-3.0) after vaccination, and the decrease was statistically significant (p < 0.001). With the multivariate regression analysis, it was shown that KPA13 reduced the exacerbation frequency 4.40 times (95% CI 1.77-10.86) compared to the previous year.
Conclusion: This study showed that vaccination of KPA13 improves the quality of life and decreases the frequency of exacerbations in COPD patients.
| Odds Ratio | %95 GA | p value | |
| Age | 1,01 | 0,97-1,06 | 0,538 |
| BMI | 0,97 | 0,86-1,08 | 0,539 |
| KPA13 administration | 4,40 | 1,77-10,86 | 0,001 |
| FEV1/FVC | 0,98 | 0,93-1,04 | 0,514 |
| FEF %25-75 | 0,99 | 0,95-1,04 | 0,770 |
| mMRC score | 1,15 | 0,68-1,91 | 0,591 |
Evaluation of factors that positively affect the reduction in exacerbation frequency by Multivariate Regression Analysis
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2139.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
